43 / 182
NUMBER OF EMPLOYEES
84
SALES, MARKETING
AND ADMINISTRATION
681
FACTORY
BUSINESS FOCUS
•
Uncompromising attention to customer service in the areas of supply,
delivery and communications
•
Maintaining and growingmarket leading positions in both established
as well as newly penetrated therapy areas
•
Expansion into adjacent categories through licensing, partnerships
and strategic alliances
•
Maximising operations with intense focus on yield, wastage, effi-
ciencies and automation
•
Focus on product mix across and within portfolios, thus supporting
sustainable and profitable growth
•
Maintaining close relationship with Government to support national
demand
•
Maintaining close relationship with all stakeholders to build trust,
demonstrate commitment and deliver on expectations.
OVERVIEW
The business is a fully integrated operation which spans regulatory,
research and development, manufacturing, marketing, sales and
distribution. Adcock IngramCritical Care not only commercialises a broad
product offering but manufactures an extensive range in its unique dual
process factory which comprises a comprehensive plastics extrusion
plant and a fully accredited pharmaceuticals manufacturing facility.
The Adcock Ingram Critical Care portfolio includes:
•
renal therapies across all the key dialysis modalities, including renal
pharmaceuticals
•
intravenous solutions, both large and small volume parenterals
•
transfusion therapies for the collection and storage of blood
•
infusion systems, invasive diagnostics and nutrition
•
bioscience and specialised pharmaceuticals, which include many
newly added formulations as well as holding a promising pipeline.
A broader segmental definition with credentials can be defined as follows:
Renal
•
In partnership with Netcare, owns
National Renal Care (NRC) which
remains the largest service provider
for renal care in South Africa.
•
Critical Care remains the largest sup-
plier of goods and services within:
–– Peritoneal Dialysis (PD), includ-
ing a uniquely modelled Renal
Home Delivery Service (RHDS)
–– Haemodialysis (HD)
–– Continuous Renal replacement
Therapy (CRRT)
–– Renal Pharmaceuticals.
Medicine Delivery
•
Largest supplier of large volume
parenterals (LVP’s) in South Africa
•
Market leader in regional anaesthe-
sia, and sterile water for irrigation
(pour water)
•
Has a comprehensive range of SVP’s
across multiple therapeutic areas
including anti-infectives, oncology,
anti-emetics, respiratory and hyp-
notics.
Transfusion Therapies
•
Fully integrated manufacturing facili-
ty for the manufacture of blood bags
and tubing
•
Largest supplier of free flowing leu-
codepletion sets and blood bags in
South Africa
•
Largest supplier to SANBS (South
African National Blood Services) with
which it has enjoyed a relationship
for more than 50 years.
Bioscience; and
Specialised
Pharmaceuticals
SALES
Public
sector
34
%
66
%
Private
sector
•
A leader in the supply of product for
Haemophilia
•
A leading supplier of speciality phar-
maceuticals including sodium poly-
styrene and one alpha hydroxylase
•
Has established a host of newly
formed strategic alliance relation-
ships over the 2016 period which
will bring participation in several
new therapy areas including:
–– Oral and injectable analgesia
–– Patient controlled analgesia
–– Oncology, and
–– Anaemia.
FIVE
SIX
THREE
ONE
FOUR
TWO
OUR PERFORMANCE
(continued)
| 39
Integrated Report 2016